Were William Guyer’s Corcept (CORT) share sales pre-planned?

Yes. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted on November 27, 2024. Such plans pre-schedule trades, indicating this sale followed an established plan rather than being timed discretionarily.

Corcept (CORT) CDO exercises options and sells 11,767 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 11,767 shares of common stock at $21.65 per share and on the same day sold 11,767 shares at a weighted average price of $36.01 per share. The sale prices ranged from $35.97 to $36.24 per share and was carried out under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 2,231 shares of common stock, plus 224 shares and 498 shares underlying unvested restricted stock awards that are scheduled to vest in full on the one-year anniversaries of their December 1, 2025 and March 2, 2026 grant dates, respectively, subject to specified conditions. The option exercised for 11,767 shares was fully exercisable before this transaction.

Insider Trade Summary 10b5-1

Net Seller: 11,767 shares ($423,730)

Net Sell 3 txns

Insider Guyer William

Role Chief Development Officer

Sold 11,767 shs ($424K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	11,767	$0.00	--
Exercise	Common Stock	11,767	$21.65	$255K
Sale	Common Stock	11,767	$36.01	$424K

Holdings After Transaction: Stock Option (right to buy) — 210,000 shares (Direct); Common Stock — 13,998 shares (Direct)

Footnotes (1)

Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Fully exercisable.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/24/2026 - 04:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2026		M		11,767	A	$21.65	13,998⁽¹⁾	D
Common Stock	03/20/2026		S⁽²⁾		11,767	D	$36.01⁽³⁾	2,231⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$21.65	03/20/2026		M			11,767	⁽⁴⁾	09/01/2031	Common Stock	11,767	$0.00	210,000	D

Explanation of Responses:

1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Corcept (CORT) executive William Guyer do in this Form 4?

William Guyer exercised options for 11,767 Corcept shares at $21.65 and sold 11,767 shares at a weighted average of $36.01. These actions converted option value into cash while leaving him with a smaller remaining common stock position.

At what prices were William Guyer’s Corcept (CORT) shares sold?

Guyer’s 11,767 Corcept shares were sold at a weighted average price of $36.01 per share. The filing states individual sale prices ranged from $35.97 to $36.24 per share, with full price breakdowns available from the company on request.

How many Corcept (CORT) shares does William Guyer hold after this transaction?

After the transactions, Guyer directly holds 2,231 Corcept common shares. In addition, footnotes show 224 and 498 shares underlying unvested restricted stock awards, which are scheduled to vest fully one year after their respective grant dates if conditions are met.

What stock option did William Guyer exercise in Corcept (CORT)?

Guyer exercised a fully exercisable stock option covering 11,767 Corcept common shares at an exercise price of $21.65 per share. The option had an expiration date of September 1, 2031, and this exercise converted those derivative rights into actual shares.

What restricted stock awards does William Guyer hold at Corcept (CORT)?

Footnotes state he holds 224 shares from a December 1, 2025 grant and 498 shares from a March 2, 2026 grant as unvested restricted stock. All shares from each grant vest on the one-year anniversary if specified service or other conditions are satisfied.